Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device - a real-world, single center, observational study - PubMed

14 hours ago

Study evaluates long-term outcomes of HeartMate 3 LVAD in 176 patients from 2016-2025.
Primary outcome was on-device survival; secondary outcomes included major adverse events.
Survival rates were 87% at 1 year, 82% at 2 years, and 61% at 5 years.
Bridge to transplant (BTT) patients showed longer survival than destination therapy (DT) patients.
Most common adverse events were device-related infections and heart failure hospitalizations.
No LVAD pump thrombosis events were recorded, highlighting improved outcomes with current devices.

Hasty Briefsbeta